NEULANDLAB2019-10-012019-12-31in-bse-fin:OneOperatingExpenses01Member NEULANDLAB2019-10-012019-12-31in-bse-fin:OneOperatingExpenses02Member NEULANDLAB2019-10-012019-12-31in-bse-fin:FourOperatingExpenses01Member NEULANDLAB2019-10-012019-12-31in-bse-fin:FourOperatingExpenses02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares NEULANDLAB 2019-04-01 2020-03-31 2020-01-16 INR Lakhs Third quarter Single segment Manufacturing of Active Pharmaceutical Ingredients 2019-10-01 2019-12-31 Unaudited Standalone 2036197000.00 10224000.00 2046421000.00 1054500000.00 0.00 -18301000.00 297197000.00 56923000.00 78172000.00 422184000.00 1890675000.00 155746000.00 0.00 155746000.00 31307000.00 14013000.00 45320000.00 0.00 110426000.00 0.00 0.00 0.00 0.00 110426000.00 -2929000.00 107497000.00 0.00 0.00 129005000.00 10 8.61 8.61 0.00 0.00 8.61 8.61 1.The financial results for the quarter and nine months ended 31 December 2019 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11 February 2020. n n2.The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder. n n3.The operations of the Company are predominantly related to the manufacture of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 Operating Segments . n n4.The Company has adopted IND AS 116 Leases effective 1 April 2019, as notified by the Ministry of Corporate Affairs (MCA) vide Companies (Indian Accounting Standard), Amendment Rules, 2109 using the modified retrospective method. The transition resulted in recognition of Right-of-Use asset & lease liability. The effect of this adoption is insignificant on the profit for the period. n n5.The Government of India, on 20 September 2019, vide the Taxation laws (Amendement) Ordinance 2019, inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income Tax at reduced rates as per the provisions/conditions defined in the said section. The Company is in the process of evaluting its position with respect to the aforesaid option. n n6.The Board of Directors had at the meeting held on 11 February 2020, declared interim dividend of Rs.2/- per equity share of face value Rs.10/- each. n n7.The EPS for quarters and nine month has not been annualised. n n8.Previous period figures have been regrouped/rearranged wherever considered necessary to confirm to the current year presentation. Single segment 2019-04-01 2019-12-31 Unaudited Standalone 5708449000.00 21097000.00 5729546000.00 3023701000.00 0.00 -82503000.00 866660000.00 145025000.00 236512000.00 1185961000.00 5375356000.00 354190000.00 0.00 354190000.00 83993000.00 17896000.00 101889000.00 0.00 252301000.00 0.00 0.00 0.00 0.00 252301000.00 -8935000.00 243366000.00 0.00 0.00 129005000.00 10 19.67 19.67 0.00 0.00 19.67 19.67 Manufacturing expenses 259791000.00 Other expenses 162393000.00 Manufacturing expenses 692500000.00 Other expenses 493461000.00